IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Alembic Completes Acquisition of Dabur Pharma

1:31 PM MDT | July 24, 2007 | DR

Pharmaceutical company Alembic (Vadodara, India) says it has completed the acquisition of the non-oncology formulation business of Dabur Pharma (New Delhi) for approximately $37 million. Alembic acquired full rights to market 24 Dabur brands, under the terms of the deal. Most of the brands are in the high-growth lifestyle therapeutic segments of cardiology, diabetology, and gynecology. Alembic is the largest player in the anti-infective drug segment in India, and aims to increase market share in the lifestyle segment. “With this acquisition, we have a ready...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa